UBS maintains Dentsply Sirona at Buy, lowers price target to $13 from $17

UBS kept Dentsply Sirona at Buy but reduced its price target to $13 from $17, a 23.5% cut. This implies a 41.9% upside from the Nov 13 close of $9.16. Recent analyst targets range from $10 to $13.

Original reporting
Published Nov 16, 2026, 4:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Dentsply Sirona at Buy, lowers price target to $13 from $17 — source image
Decision brief

The 30-second read

$XRAYBearishLow
01

Why it matters

A lower price target can influence short-term positioning and expectations, but the lack of new operational or financial disclosures in the text limits the actionable impact.

02

Market read

Traders may adjust valuation expectations for XRAY based on UBS’s revised target, but the note is not a fundamental catalyst by itself.

03

What to watch

Price-target changes can lag or reflect model updates rather than new information; without thesis details, traders may discount the move’s durability.

Relevance 4/10Novelty 4/10Timing: as soon as the note is digested by the market, likely same-day/next-session sentiment

Background

The article summarizes UBS’s latest analyst note on Dentsply Sirona, including a maintained Buy rating and a reduced price target.

Company-level read

Ticker impact

$XRAYBearishMedium confidence
Context

UBS maintained Dentsply Sirona at Buy and cut its price target to $13 from $17, implying a large change in valuation expectations.

Expected impact

Likely mild-to-moderate downside bias as the market reprices the analyst’s valuation framework, partially offset by the unchanged Buy rating.

Evidence & confidence

This is a sell-side price-target revision without new company fundamentals in the text; directionally, a lower target tends to weigh on sentiment, but the maintained Buy reduces the magnitude.

Market effects

Limited spillover to dental/medical-diagnostics peers because the article is a single-bank target change, not sector guidance or regulatory action.

No clear regional macro linkage beyond general US equity sentiment.

Minimal global relevance; this is a US-listed single-name analyst update.

Counterpoint

The unchanged Buy rating may signal the analyst still sees upside, so the market may focus more on the rating than the lower target.

Key entities

  • Dentsply Sirona

    UBS maintained a Buy rating and lowered its price target to $13 from $17.

  • UBS

    Issued the maintained rating and revised price target referenced in the article.

Related articles

$XRAYHighAI 8/10

XRAY Q3 2026 deep dive: revenue shortfall and guidance cut amid dental market headwinds

XRAY reported Q3 2026 revenue of $836M, missing estimates by 2.7%, with adjusted EPS of $0.29, missing by 6.2%. The company cut full-year revenue guidance to $3.5B and adjusted EPS to $1.25. Growth in Wellspect Healthcare and U.S. dental segments was offset by inventory reductions and market challenges in EMEA and the Middle East. Management highlighted cost-saving initiatives and investments in sales and education.

MedAI 8/10

Dentsply Sirona Lowers 2026 EPS Outlook After Third-Quarter Sales Slide

Dentsply Sirona (XRAY) lowered its 2026 adjusted EPS outlook to $1.20-$1.30 after Q3 sales fell 7.6% to $836M and adjusted EPS dropped 29.4% to $0.29. The company expects $3.5B in 2026 sales, down from its prior $3.5B-$3.6B forecast. Q3 net loss was $2M, improved from a $427M loss in Q3 2025. Sales varied across business segments, with Wellspect Healthcare up 10.1%.

$XRAYMedAI 8/10

DENTSPLY SIRONA Q3 Earnings Call Highlights

DENTSPLY SIRONA reported Q3 earnings with a $39M pretax accounting benefit, not expected to recur. Operating cash flow declined to $32M. Wellspect Healthcare revenue rose 10%, while dental segments saw declines. The company repurchased 1.2M shares and plans $120M in savings for 2026. Management expects continued investment in growth areas.

HighAI 8/10

DENTSPLY (XRAY) Q3 2026 Earnings Call Transcript

DENTSPLY SIRONA (XRAY) reported Q3 2026 revenue of $836M, down 7.6%, and adjusted EPS of $0.29. The company lowered its full-year guidance to $3.5B in sales and $1.20-$1.30 in adjusted EPS, citing business pressures and investment in growth initiatives. Wellspect Healthcare saw record sales growth, while other segments faced challenges.

$XRAYMedAI 8/10

Dentsply Sirona (XRAY) stock trades down, here is why

Dentsply Sirona (XRAY) shares fell 7% after reporting a Q3 2026 GAAP loss of $0.01 per share and lowering its full-year outlook. Net sales were $836M, missing estimates. The company now expects 2026 net sales of $3.5B and adjusted EPS of $1.20-$1.30. Shares are down 17.4% YTD and 36.6% below their 52-week high.